A competitive ELISA for quantifying serum CD147: Reduction of soluble cd147 levels in cancer patient sera

Hybridoma

Volumn 29, Issue 1, 2010, Pages 45-52

  Moonsom, Seangdeun ^a   Tayapiwatana, Chatchai ^a   Wongkham, Sopit ^b   Kongtawelert, Prachya ^c   Kasinrerk, Watchara ^a  

^a CHIANG MAI UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

^c Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

CD147 ANTIGEN; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN;

ANTIGEN DETECTION; ARTICLE; BILE DUCT CARCINOMA; BLOOD ANALYSIS; CANCER PATIENT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS; HOMEOSTASIS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD147; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; PLASMIDS;

EID: 77749270826     PISSN: 15540014     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.2009.0096     Document Type: Article

References (58)

1. Tang J, Wu YM, Zhao P, Yang XM, Jiang JL, and Chen ZN: Overexpression of HAb18G/CD147 promotes invasion and metastasis via alpha3beta1 integrin mediated FAK-paxillin and FAK-PI3K-Ca2+ pathways. Cell Mol Life Sci 2008; 65:2933-2942.
2. Gabison EE, Hoang-Xuan T, Mauviel A, and Menashi S: EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair. Biochimie 2005;87:361-368.
3. Renno T, Wilson A, Dunkel C, Coste I, Maisnier-Patin K, Benoit de Coignac A, Aubry JP, Lees RK, Bonnefoy JY, MacDonald HR, and Gauchat JF: A role for CD147 in thymic development. J Immunol 2002;168:4946-4950.
4. Major TC, Liang L, Lu X, Rosebury W, and Bocan TM: Extracellular matrix metalloproteinase inducer (EMMPRIN) is induced upon monocyte differentiation and is expressed in human atheroma. Arterioscler Thromb Vasc Biol 2002;22: 1200-1207.
5. Kasinrerk W, Fiebiger E, Stefanova I, Baumruker T, Knapp W, and Stockinger H: Human leukocyte activation antigen M6, a member of the Ig superfamily, is the species homologue of rat OX-47, mouse basigin, and chicken HT7 molecule. J Immunol 1992;149:847-854.
6. Kasinrerk W, Tokrasinwit N, and Phunpae P: CD147 monoclonal antibodies induce homotypic cell aggregation of monocytic cell line U937 via LFA-1/ICAM-1 pathway. Immunology 1999;96:184-192.
7. Igakura T, Kadomatsu K, Taguchi O, Muramatsu H, Kaname T, Miyauchi T, Yamamura K, Arimura K, and Muramatsu T: Roles of basigin, a member of the immunoglobulin superfamily, in behavior as to an irritating odor, lymphocyte response, and blood-brain barrier. Biochem Biophys Res Commun 1996;224:33-36.
8. Koch C, Staffler G, Huttinger R, Hilgert I, Prager E, Cerny J, Steinlein P, Majdic O, Horejsi V, and Stockinger H: T cell activation-associated epitopes of CD147 in regulation of the T cell response, and their definition by antibody affinity and antigen density. Int Immunol 1999;11:777-786.
9. Staffler G, Szekeres A, Schutz GJ, Saemann MD, Prager E, Zeyda M, Drbal K, Zlabinger GJ, Stulnig TM, and Stockinger H: Selective inhibition of T cell activation via CD147 through novel modulationoflipid rafts. J Immunol 2003;171:1707-1714.
10. Chiampanichayakul S, Peng-in P, Khunkaewla P, Stockinger H, and Kasinrerk W: CD147 contains different bioactive epitopes involving the regulation of cell adhesion and lymphocyte activation. Immunobiology 2006;211:167-178.
11. Khunkaewla P, Schiller HB, Paster W, Leksa V, Cermak L, Andera L, Horejsi V, and Stockinger H: LFA-1-mediated leukocyte adhesion regulated by interaction of CD43 with LFA-1 and CD147. Mol Immunol 2008;45:1703-1711.
12. Reimers N, Zafrakas K, Assmann V, Egen C, Riethdorf L, Riethdorf S, Berger J, Ebel S, Janicke F, Sauter G, and Pantel K: Expression of extracellular matrix metalloproteases in-ducer on micrometastatic and primary mammary carcinoma cells. Clin Cancer Res 2004;10:3422-3428.
13. Tang Y, Nakada MT, Kesavan P, McCabe F, Millar H, Rafferty P, Bugelski P, and Yan L: Extracellular matrix me-talloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res 2005;65:3193-3199.
14. Nabeshima K, Iwasaki H, Koga K, Hojo H, Suzumiya J, and Kikuchi M: Emmprin (basigin/CD147): matrix metallopro-teinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol Int 2006;56:359-367.
15. Sun J, and Hemler ME: Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metallo-proteinase inducer interactions. Cancer Res 2001;61:2276-2281.
16. Gabison EE, Mourah S, Steinfels E, Yan L, Hoang-Xuan T, Watsky MA, De Wever B, Calvo F, Mauviel A, and Menashi S: Differential expression of extracellular matrix metallo-proteinase inducer (CD147) in normal and ulcerated corneas: role in epithelio-stromal interactions and matrix metallo-proteinase induction. Am J Pathol 2005;166:209-219.
17. Yan L, Zucker S, and Toole BP: Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb Haemost 2005;93:199-204.
18. Zhong WD, Han ZD, He HC, Bi XC, Dai QS, Zhu G, Ye YK, Liang YX, Qin WJ, Zhang Z, Zeng GH, and Chen ZN: CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer. Oncology 2008;75:230-236.
19. Jia L, Zhou H, Wang S, Cao J, Wei W, and Zhang J: Deglycosylation of CD147 down-regulates matrix metallo-proteinase-11 expression and the adhesive capability of murine hepatocarcinoma cell HcaF in vitro. IUBMB Life 2006; 58:209-216.
20. Biswas C: Collagenase stimulation in cocultures of human fi-broblasts and human tumorcells. Cancer Lett 1984;24:201-207.
21. Hanata K, Yamaguchi N, Yoshikawa K, Mezaki Y, Miura M, Suzuki S, Senoo H, and Ishikawa K: Soluble EMMPRIN (extra-cellular matrix metalloproteinase inducer) stimulates the migration of HEp-2 human laryngeal carcinoma cells, accompanied by increased MMP-2 production in fibroblasts. Arch Histol Cytol 2007;70:267-277.
22. Millimaggi D, Mari M, D'Ascenzo S, Carosa E, Jannini EA, Zucker S, Carta G, Pavan A, and Dolo V: Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells. Neoplasia 2007;9:349-357.
23. Zhang W, Erkan M, Abiatari I, Giese NA, Felix K, Kayed H, Buchler MW, Friess H, and Kleeff J: Expression of extracellular matrix metalloproteinase inducer (EMMPRIN/CD147) in pancreatic neoplasm and pancreatic stellate cells. Cancer Biol Ther 2007;6:218-227.
24. Zhifan X, Jie L, Shioqiong C, Zhihui Z, Li L, Zhengying L, Yanru K, and Lina X: Significance of the expression and serum levels of CD147 and MMP-2 in patients with colo-rectal cancer. Chin J Clin Oncol 2008;35:1064-1067.
25. Krebber A, Bornhauser S, Burmester J, Honegger A, Willuda J, Bosshard HR, and Pluckthun A: Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system. J Immunol Methods 1997;201:35-55.
26. Tayapiwatana C, Chotpadiwetkul R, and Kasinrerk W: A novel approach using streptavidin magnetic bead-sorted in vivo biotinylated survivin for monoclonal antibody production. J Immunol Methods 2006;317:1-11.
27. Qian AR, Zhang W, Cao JP, Yang PF, Gao X, Wang Z, Xu HY, Weng YY, and Shang P: Down regulation of CD147 expression alters cytoskeleton architecture and inhibits gelatinase production and SAPK pathway in human hepatocellular carcinoma cells. J Exp Clin Cancer Res 2008;27:50.
28. Caudroy S, Polette M, Tournier JM, Burlet H, Toole B, Zucker S, and Birembaut P: Expression of the extracellular matrix metalloproteinase inducer (EMMPRIN) and the matrix me-talloproteinase-2 in bronchopulmonary and breast lesions. J Histochem Cytochem 1999;47:1575-1580.
29. Sidhu SS, Mengistab AT, Tauscher AN, LaVail J, and Basbaum C: The microvesicle as a vehicle for EMMPRIN in tumor-stromal interactions. Oncogene 2004;23:956-963.
30. Egawa N, Koshikawa N, Tomari T, Nabeshima K, Isobe T, and Seiki M: Membrane type 1 matrix metalloproteinase (MT1-MMP/MMP-14) cleaves and releases a 22-kDa extracellular matrix metalloproteinase inducer (EMMPRIN) fragment from tumor cells. J Biol Chem 2006;281:37576-37585.
31. Taylor PM, Woodfield RJ, Hodgkin MN, Pettitt TR, Martin A, Kerr DJ, and Wakelam MJ: Breast cancer cell-derived EMMPRIN stimulates fibroblast MMP2 release through a phospholipase A(2) and 5-lipoxygenase catalyzed pathway. Oncogene 2002;21:5765-5772.
32. Tang Y, Kesavan P, Nakada MT, and Yan L: Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN. Mol Cancer Res 2004;2:73-80.
33. Bidart JM, Thuillier F, Augereau C, Chalas J, Daver A, Jacob N, Labrousse F, and Voitot H: Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem 1999;45:1695-1707.
34. Hoshino M, Kawashima H, Ogose A, Kudo N, Ariizumi T, Hotta T, Umezu H, Hatano H, Morita T, Nishio J, Iwasaki H, and Endo N: Serum CA 125 expression as a tumor marker for diagnosis and monitoring the clinical course of epithelioid sarcoma. J Cancer Res Clin Oncol 2010;136:457-464.
35. Taylor DD, Lyons KS, and Gercel-Taylor C: Shed membrane fragment-associated markers for endometrial and ovarian cancers. Gynecol Oncol 2002;84:443-448.
36. Chapman-Smith A, and Cronan JE Jr: In vivo enzymatic protein biotinylation. Biomol Eng 1999;16:119-125.
37. Tragoolpua K, Intasai N, Kasinrerk W, Mai S, Yuan Y, and Tayapiwatana C: Generation of functional scFv intrabody to abate the expression of CD147 surface molecule of 293A cells. BMC Biotechnol 2008;8:5.
38. Santala V, and Lamminmaki U: Production of a biotinylated single-chain antibody fragment in the cytoplasm of Escher-ichia coli. J Immunol Methods 2004;284:165-175.
39. Prinz WA, Aslund F, Holmgren A, and Beckwith J: The role of the thioredoxin and glutaredoxin pathways in reducing protein disulfide bonds in the Escherichia coli cytoplasm. J Biol Chem 1997;272:15661-15667.
40. Laurent TC, and Fraser JR: Hyaluronan. FASEB J 1992;6: 2397-2404.
41. Posey JT, Soloway MS, Ekici S, Sofer M, Civantos F, Duncan RC, and Lokeshwar VB: Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL1) for prostate cancer. Cancer Res 2003;63:2638-2644.
42. Passerotti CC, Bonfim A, Martins JR, Dall'Oglio MF, Sampaio LO, Mendes A, Ortiz V, Srougi M, Dietrich CP, and Nader HB: Urinary hyaluronan as a marker for the presence of residual transitional cell carcinoma of the urinary bladder. Eur Urol 2006;49:71-75.
43. Iacono KT, Brown AL, Greene MI, and Saouaf SJ: CD147 immunoglobulin superfamily receptor function and role in pathology. Exp Mol Pathol 2007;83:283-295.
44. Jiang JL, and Tang J: CD147 and its interacting proteins in cellular functions. Sheng Li Xue Bao 2007;59:517-523.
45. Yao Q, Li M, Yang H, Chai H, Fisher W, and Chen C: Roles of cyclophilins in cancers and other organ systems. World J Surg 2005;29:276-280.
46. Fillies T, Werkmeister R, van Diest PJ, Brandt B, Joos U, and Buerger H: HIF1-alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor. BMC Cancer 2005;5:84.
47. Choi KJ, Piao YJ, Lim MJ, Kim JH, Ha J, Choe W, and Kim SS: Overexpressed cyclophilin A in cancer cells renders resistance to hypoxia-and cisplatin-induced cell death. Cancer Res 2007;67:3654-3662.
48. Shen J, Person MD, Zhu J, Abbruzzese JL, and Li D: Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel elec-trophoresis and mass spectrometry. Cancer Res 2004;64: 9018-9026.
49. Rey O, Baluda MA, and Park NH: Differential gene expression in neoplastic and human papillomavirus-immortalized oral keratinocytes. Oncogene 1999;18:827-831.
50. Howard BA, Zheng Z, Campa MJ, Wang MZ, Sharma A, Haura E, Herndon JE 2nd, Fitzgerald MC, Bepler G, and Patz EF Jr: Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer. Lung Cancer 2004;46:313-323.
51. Howard BA, Furumai R, Campa MJ, Rabbani ZN, Vujaskovic Z, Wang XF, and Patz EF Jr: Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo. Cancer Res 2005; 65:8853-8860.
52. Tegeder I, Schumacher A, John S, Geiger H, Geisslinger G, Bang H, and Brune K: Elevated serum cyclophilin levels in patients with severe sepsis. J Clin Immunol 1997;17:380-386.
53. Billich A, Winkler G, Aschauer H, Rot A, and Peichl P: Presence of cyclophilin A in synovial fluids of patients with rheumatoid arthritis. J Exp Med 1997;185:975-980.
54. Jin ZG, Lungu AO, Xie L, Wang M, Wong C, and Berk BC: Cyclophilin A is a proinflammatory cytokine that activates en-dothelial cells. Arterioscler Thromb Vasc Biol 2004;24:1186-1191.
55. Tischoff I, and Tannapfel A: [Hepatocellular carcinoma and cholangiocarcinoma different prognosis, pathogenesis and therapy]. Zentralbl Chir 2007;132:300-305.
56. Songsivilai S, Dharakul T, and Kanistanon D: Hepatitis C virus genotypes in patients with hepatocellular carcinoma and cholangiocarcinoma in Thailand. Trans R Soc Trop Med Hyg 1996;90:505-507.
57. Franca AV, Elias Junior J, Lima BL, Martinelli AL, and Carrilho FJ: Diagnosis, staging and treatment of hepatocel-lular carcinoma. Braz J Med Biol Res 2004;37:1689-1705.
58. Sripa B, and Kaewkes S: Localisation of parasite antigens and inflammatory responses in experimental opisthorch-iasis. Int J Parasitol 2000;30:735-740.